Gyre Therapeutics (NASDAQ: GYRE)
$10.79
(-10.1%)
-$1.21
Price as of January 3, 2025, 4:00 p.m. ET
Gyre Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Gyre Therapeutics Company Info
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The company was founded on March 7, 1997 and is headquartered in San Diego, CA.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.